Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
CNTA 11.04.2024
About Gravity Analytica
Recent News
Recent Filings
BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) --Centessa Pharmaceuticals plc(Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Event:Guggenheim Healthcare Innovation ConferenceDate:November 13, 2024Location:Boston, MAFireside Chat:9:00 AM ET
Event:Jefferies London Healthcare ConferenceDate:November 19, 2024Location:London, UKFireside Chat: 1:30 PM GMT
Event:7thAnnual Evercore HealthCONx ConferenceDate:December 5, 2024Location:Miami, FLFireside Chat:10:00 AM ET
Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website athttps://investors.centessa.com/.
About Centessa PharmaceuticalsCentessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visitwww.centessa.com, which does not form part of this release.
Contact:
Kristen K. Sheppard, Esq.SVP of Investor Relationsinvestors@centessa.com
Source:Centessa Pharmaceuticals plc